BC Children's Hospital

Running trials

• Not yet recruiting

  Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy

  NCT07842328· University of British Columbia· Source

• Enrolling by invitation

  Intelligent Care Platform - Quasi-Experimental Trial

  NCT07712809· University of British Columbia· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· argenx· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Moisturization and Skin Hydration Study

  NCT07270965· University of British Columbia· Source

• Recruiting

  A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

  NCT07160634· Phase 3· Solid Biosciences Inc.· Source

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· C17 Council· Source

• Recruiting

  Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation

  NCT07095244· University of British Columbia· Source

• Recruiting

  Portable Sleep Monitors in Children With Autism Spectrum Disorder

  NCT07367022· Lena Xiao· Source

• Recruiting

  CANnabinoids in Pediatric ONCology

  NCT05754840· Phase 1/2· University of Manitoba· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Incyte Corporation· Source

• Recruiting

  The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents

  NCT07176767· Lena Xiao· Source

• Not yet recruiting

  Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, Resource Program: How Does it Work?

  NCT06020274· University of Regina· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  WeRoaM: Wearable Remote Monitoring in Heart Failure

  NCT06969560· University of Alberta· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

  NCT06208735· Phase 1· British Columbia Cancer Agency· Source

• Recruiting

  Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

  NCT06654752· University of Washington, the Collaborative Health Studies Coordinating Center· Source

• Active, not recruiting

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

  NCT06460506· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With Spinal Muscular Atrophy

  NCT06396325· Maryam Oskoui, MD, MSc, FRCPC, FAAN· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  NS-050/NCNP-03 in Boys With DMD (Meteor50)

  NCT06053814· Phase 1/2· NS Pharma, Inc.· Source

• Active, not recruiting

  STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

  NCT06571383· Phase 4· Novo Nordisk A/S· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Recruiting

  Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

  NCT06208657· Phase 1/2· Australian & New Zealand Children's Haematology/Oncology Group· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

• Not yet recruiting

  Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour

  NCT06362434· University Health Network, Toronto· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Vascular Complications in Children From T1D Diagnosis

  NCT05790785· University of British Columbia· Source

• Active, not recruiting

  NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

  NCT05996003· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

  NCT05933057· Phase 3· Italfarmaco· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  NCT05761171· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05995353· Phase 3· AbbVie· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Recruiting

  TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  NCT05848687· Phase 1/2· Tanja Andrea Gruber· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

  NCT05987449· Phase 1/2· Hoffmann-La Roche· Source

• Enrolling by invitation

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  NCT05286788· Phase 2· Nationwide Children's Hospital· Source

• Active, not recruiting

  Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

  NCT05457556· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05693142· Phase 2/3· REGENXBIO Inc.· Source

• Active, not recruiting

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Recruiting

  Paediatric Syncope in the Emergency Department

  NCT05555771· Dr. Victoria Claydon· Source

Showing 50 of 87.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers19 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Cystic fibrosis5 recruiting
• Acute myeloid leukaemia2 recruiting
• Cerebral palsy2 recruiting
• Crohn's disease2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Kidney cancer2 recruiting
• Neuroblastoma2 recruiting
• Obstructive sleep apnoea2 recruiting
• Spinal muscular atrophy2 recruiting
• Type 1 diabetes2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Down syndrome1 recruiting
• Epilepsy1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Hydrocephalus1 recruiting
• Insomnia1 recruiting
• Mantle cell lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Postural tachycardia syndrome (POTS)1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

  NCT06506773· Vertex Pharmaceuticals Incorporated· Source

• Terminated

  A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

  NCT06079736· Phase 2· PepGen Inc· Source

• Completed

  App-based Consent for Pediatric Clinical Research

  NCT05880147· University of British Columbia· Source

• Completed

  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

  NCT05864846· Phase 4· Jazz Pharmaceuticals· Source

• Completed

  Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

  NCT05882357· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

• Completed

  A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

  NCT05115110· Phase 2/3· Hoffmann-La Roche· Source

• Completed

  The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

  NCT05025852· Mount Sinai Hospital, Canada· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Completed

  A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

  NCT05185622· Phase 2· Santhera Pharmaceuticals· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Takeda· Source

• Terminated

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· Phase 1· National Cancer Institute (NCI)· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source

• Completed

  HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

  NCT04670016· University of Calgary· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

  NCT04183790· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

  NCT03632343· The Hospital for Sick Children· Source

• Completed

  Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers

  NCT03365687· Phase 3· Professor Francine Ducharme· Source

• Completed

  A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

  NCT03655678· Phase 2/3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

  NCT03206021· Phase 1· The Hospital for Sick Children· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· University of Calgary· Source

• Completed

  Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

  NCT02879643· Phase 1· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Incyte Corporation· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

  NCT01798004· Phase 1· Children's Oncology Group· Source

• Recruiting

  Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

  NCT01949129· Phase 2/3· St. Anna Kinderkrebsforschung· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Terminated

  Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

  NCT01247207· Phase 3· PTC Therapeutics· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Children's Oncology Group· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Children's Oncology Group· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Collecting and Storing Tissue From Young Patients With Cancer

  NCT00898755· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Children's Oncology Group· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Children's Oncology Group· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease26 works · 5 trials
• Acute lymphoblastic leukaemia13 works · 21 trials
• Hodgkin lymphoma11 works · 0 trials
• Hydrocephalus8 works · 2 trials
• Thalassaemia6 works · 1 trial